CRL Stock

Charles River and Akron Bio are working together to improve their operations by adding CGMP materials to the Cell Therapy Platform.

CRL has strong potential in the RMS sector and good financial health, which makes it an attractive option for investors.

Charles River has launched a new program aimed at supporting early-stage biotechnology developers.

Investors feel positive about CRL stock because of its promising RMS potential and its efforts for growth through acquisitions.

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is greater than the decline in revenues from the DSA segment.

While the revenue and earnings per share (EPS) for Charles River (CRL) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

Charles River Laboratories (CRL) reported quarterly earnings of $2.59 per share, which is higher than the Zacks Consensus Estimate of $2.43 per share. This is a decrease compared to earnings of $2.72 per share from the same period last year.

Charles River (CRL) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories has announced the date for their third-quarter 2024 earnings release and conference call.